VGF, VGF nerve growth factor inducible, 7425

N. diseases: 63; N. variants: 2
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0025268
Disease: Multiple Endocrine Neoplasia Type 2a
Multiple Endocrine Neoplasia Type 2a 		0.010 AlteredExpression disease BEFREE We demonstrated that all forms of RET oncoprotein, including RET chimeric oncoproteins found in human papillary thyroid carcinomas (RET/PTC) as well as RET oncoproteins found in patients with multiple endocrine neoplasia type 2A and 2B (2A/RET and 2B/RET) can induce vgf promoter activity in PC12 cells. 9478934 1998
CUI: C0002736
Disease: Amyotrophic Lateral Sclerosis
Amyotrophic Lateral Sclerosis 		0.060 Biomarker disease LHGDN Identification of potential CSF biomarkers in ALS. 16481598 2006
CUI: C0020507
Disease: Hyperplasia
Hyperplasia 		0.010 Biomarker phenotype LHGDN Peptide products of the neurotrophin-inducible gene vgf are produced in human neuroendocrine cells from early development and increase in hyperplasia and neoplasia. 17440014 2007
CUI: C0036341
Disease: Schizophrenia
Schizophrenia 		0.360 Biomarker disease BEFREE In a sample of 245 nuclear families (n=1074) originating from the same geographical region as the families revealing the linkage, SNP and microsatellite association analyses of the four regional candidate genes, GRM3, RELN, SEMA3A and VGF, revealed no significant association to the clinical diagnosis of schizophrenia. 17684500 2008
CUI: C0027627
Disease: Neoplasm Metastasis
Neoplasm Metastasis 		0.010 AlteredExpression phenotype BEFREE Moreover, the secreted proteome of the MRJ(L)-expressing cells exhibited reduced levels of tumor progression and metastasis promoting secreted proteins, such as SPP1 (osteopontin), AZGP1 (zinc binding alpha2-glycoprotein 1), SPARC (osteonectin), NPM1 (nucleophosmin) and VGF (VGF nerve growth factor inducible). 18328103 2008
CUI: C0002736
Disease: Amyotrophic Lateral Sclerosis
Amyotrophic Lateral Sclerosis 		0.060 Biomarker disease BEFREE Previous proteomic evidence revealed that the content of certain peptide fragments including Vgf-derived peptide aa 398-411 (Vgf(398-411)) of the precursor Vgf protein in the cerebral spinal fluid (CSF) correctly identified patients with ALS from normal and disease controls. 18432310 2008
CUI: C0151786
Disease: Muscle Weakness
Muscle Weakness 		0.010 AlteredExpression phenotype LHGDN Vgf is a novel biomarker associated with muscle weakness in amyotrophic lateral sclerosis (ALS), with a potential role in disease pathogenesis. 18432310 2008
CUI: C0011570
Disease: Mental Depression
Mental Depression 		0.340 Biomarker disease PSYGENET Although LTP was normal in slices from VGF knock-out mice, LTD could not be induced, and VGF mutant mice were impaired in hippocampal-dependent spatial learning and contextual fear conditioning tasks. 18815270 2008
CUI: C0011581
Disease: Depressive disorder
Depressive disorder 		0.340 Biomarker disease PSYGENET Although LTP was normal in slices from VGF knock-out mice, LTD could not be induced, and VGF mutant mice were impaired in hippocampal-dependent spatial learning and contextual fear conditioning tasks. 18815270 2008
CUI: C1269683
Disease: Major Depressive Disorder
Major Depressive Disorder 		0.050 AlteredExpression disease BEFREE Brains from persons with major depressive disorder reveal decreased expression for genes in glutamate transport and metabolism, neurotrophic signaling (eg, FGF, BDNF and VGF), and MAP kinase pathways. 18923405 2009
CUI: C0041696
Disease: Unipolar Depression
Unipolar Depression 		0.030 AlteredExpression disease BEFREE Brains from persons with major depressive disorder reveal decreased expression for genes in glutamate transport and metabolism, neurotrophic signaling (eg, FGF, BDNF and VGF), and MAP kinase pathways. 18923405 2009
CUI: C0011570
Disease: Mental Depression
Mental Depression 		0.340 Biomarker disease PSYGENET We summarize experimental data describing the roles of BDNF, VGF and other neuropeptides in depression and how they may be acting through the generation of new neurons and altered synaptic activity. 18983874 2009
CUI: C0011581
Disease: Depressive disorder
Depressive disorder 		0.340 Biomarker disease PSYGENET We summarize experimental data describing the roles of BDNF, VGF and other neuropeptides in depression and how they may be acting through the generation of new neurons and altered synaptic activity. 18983874 2009
CUI: C0525045
Disease: Mood Disorders
Mood Disorders 		0.310 Biomarker group PSYGENET Our data provide further support to the role of VGF in mood disorders and suggest that VGF could be a more specific biomarker for treatment responsiveness. 20164831 2010
CUI: C0525045
Disease: Mood Disorders
Mood Disorders 		0.310 Biomarker group BEFREE Our data provide further support to the role of VGF in mood disorders and suggest that VGF could be a more specific biomarker for treatment responsiveness. 20164831 2010
CUI: C0344315
Disease: Depressed mood
Depressed mood 		0.050 AlteredExpression phenotype BEFREE Moreover, VGF mRNA levels were significantly reduced in drug-free depressed patients, as compared with controls, and were modulated in response to effective antidepressant treatment. 20164831 2010
CUI: C0011570
Disease: Mental Depression
Mental Depression 		0.340 Biomarker disease PSYGENET Recent studies demonstrate that the neuropeptide VGF (nonacronymic) is regulated in the hippocampus by antidepressant therapies and animal models of depression and that acute VGF treatment has antidepressant-like activity in animal paradigms. 20631166 2010
CUI: C0011570
Disease: Mental Depression
Mental Depression 		0.340 Biomarker disease BEFREE Recent studies demonstrate that the neuropeptide VGF (nonacronymic) is regulated in the hippocampus by antidepressant therapies and animal models of depression and that acute VGF treatment has antidepressant-like activity in animal paradigms. 20631166 2010
CUI: C0011581
Disease: Depressive disorder
Depressive disorder 		0.340 Biomarker disease PSYGENET Recent studies demonstrate that the neuropeptide VGF (nonacronymic) is regulated in the hippocampus by antidepressant therapies and animal models of depression and that acute VGF treatment has antidepressant-like activity in animal paradigms. 20631166 2010
CUI: C0011581
Disease: Depressive disorder
Depressive disorder 		0.340 Biomarker disease BEFREE Recent studies demonstrate that the neuropeptide VGF (nonacronymic) is regulated in the hippocampus by antidepressant therapies and animal models of depression and that acute VGF treatment has antidepressant-like activity in animal paradigms. 20631166 2010
CUI: C0005586
Disease: Bipolar Disorder
Bipolar Disorder 		0.310 Biomarker disease PSYGENET The dysregulation of VGF in bipolar disorder as well as the behavioral effects of the neuropeptide similar to LiCl suggests that VGF may underlie the pathophysiology of bipolar disorder. 20631166 2010
CUI: C0005586
Disease: Bipolar Disorder
Bipolar Disorder 		0.310 Biomarker disease BEFREE The dysregulation of VGF in bipolar disorder as well as the behavioral effects of the neuropeptide similar to LiCl suggests that VGF may underlie the pathophysiology of bipolar disorder. 20631166 2010
CUI: C0344315
Disease: Depressed mood
Depressed mood 		0.050 Biomarker phenotype BEFREE Recent studies demonstrate that the neuropeptide VGF (nonacronymic) is regulated in the hippocampus by antidepressant therapies and animal models of depression and that acute VGF treatment has antidepressant-like activity in animal paradigms. 20631166 2010
CUI: C0233514
Disease: Abnormal behavior
Abnormal behavior 		0.040 Biomarker phenotype BEFREE However, the role of VGF in human psychiatric disorders is unknown. 20631166 2010
CUI: C0004936
Disease: Mental disorders
Mental disorders 		0.030 Biomarker group BEFREE However, the role of VGF in human psychiatric disorders is unknown. 20631166 2010